AzTrials
AzTrials

IOL, CataractNCT07099079

Post-Market Clinical Follow-Up Study on the Rotational Stability of an Intraocular Lens After Cataract Surgery

An observational study of IOL, Cataract, run by Rayner Intraocular Lenses Limited.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. Read more about this study

Who is it for?
Ages 22 years and older
Conditions the study is for
IOL, Cataract
How many people
92 participants
Where
No sites listed yet
Study dates
Nov 2026to Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients aged 22 years or older who are scheduled for bilateral cataract surgery as part of routine clinical care and are in accordance with the study's inclusion and exclusion criteria.

Eligible subjects must meet all the following inclusion criteria in both eyes.

  1. Male or female, 22 years or older at the pre-operative visit who have cataract in both eyes and who are eligible for phacoemulsification cataract surgery
  2. Subjects who are projected to have best corrected distance visual acuity 0.20 logMAR (20/30) or better in both eyes after IOL implantation by investigator estimation
  3. Clear intraocular media other than cataract
  4. Contact lens wearers must demonstrate stability of biometry in both eyes
  5. Have the capability to understand and sign an EC approved informed consent form and privacy authorization in accordance with local regulations
  6. Female subjects must be 1-year postmenopausal, surgically sterilized, or if childbearing potential must use a stabilized and acceptable form of contraception from the beginning throughout the end of the study. Stabilized and acceptable contraception methods include at least one of the following: intrauterine (intrauterine device) or hormonal (oral, injection, patch, implant, ring) for at least 3 months, barrier with spermicide (condom, diaphragm), or abstinence.
  7. Have pre-existing corneal astigmatism not exceeding 1.25 D in both eyes as determined by keratometry
  8. Dilated pupil size 5.5 mm or greater to allow visualization of the IOL orientation marks post-operatively in both eyes

Eligible subjects must not meet any of the following exclusion criteria. Subjects may not participate if either eye meets any of the ocular exclusion criteria:

  1. Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK / LASEK / PRK, SMILE, astigmatic keratotomy and limbal relaxing incisions in any eye
  2. Diagnosed degenerative visual disorders (e.g. macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) that are predicted to cause future acuity losses to a level of 0.20 logMAR (20/30) or worse
  3. Significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g. pseudoexfoliation syndrome, any iris pathology)
  4. Subjects with conditions associated with increased risk of zonular rupture (that may affect post-operative centration or tilt of IOL) in any eye
  5. Potentially occludable angle or ciliary body tumor, or other pathology that might increase risk to subject safety, based on adequate diagnostics e.g. gonioscopic, anterior OCT observation
  6. Subjects reasonably expected to require secondary ocular surgical intervention or laser treatment (other than YAG capsulotomy)
  7. Subjects with clinically significant corneal pathology, potentially affecting corneal topography
  8. Subjects with traumatic cataract in any eye
  9. Currently participating in a drug or device clinical trial, or having participated in such a trial within 30 days prior to the pre-operative visit
  10. Subjects with any other serious ocular pathology (e.g. severe dry eye, history of intraocular inflammation, history of retinal surgery or retinal laser procedure) or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study
  11. Clinically significant, uncontrolled glaucoma with expected negative impact on IOL Rotational Stability and / or visual acuity outcomes in one or both eyes
  12. Use of medications known to interfere with visual performance, pupil dilation, or iris structure within 30 days of the pre-operative visit, at the discretion of the investigator
  13. Pregnant or nursing females
  14. Pre-operative corneal astigmatism above 1.25D as determined by keratometry
  15. Irregular astigmatism in any eye Additional Exclusion Criteria at the Time of Surgery: Subjects who do not meet exclusion criteria described in section 6.2 and are enrolled in the study may present findings during surgery that preclude inclusion of performance data in the investigation and thus need to be excluded from data collection post operatively. The following general exclusion criteria shall be considered during surgery for either eye:
  16. zonular instability;
  17. need for iris manipulation;
  18. capsular fibrosis or other opacity;
  19. inability to fixate IOL in desired position

If the IOL has touched the eye, it should be noted if the reason for exclusion is related to the IOL itself and/or any (e.g. IOL or insertion device defect causing capsular damage, malfunction of insertion device).

If the IOL has touched the eye, the subject should be followed, for safety, until completion of the investigation.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Pavel Stodulka, MD, PhD, FEBOS-CR contact

+420 577 202 2

stodulka@lasik.cz

About this study

Official title: Post-Market Clinical Follow-up Trial to Investigate the Rotational Stability of the Hydrophobic Intraocular Lens RAO800S

The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. The main question it aims to answer is how stable the RayOne RAO800S lens is approximately 5 months (120 to 150 days) after surgery day. Participants are adults already scheduled to undergo cataract surgery as part of clinical routine. They will be asked to attend regular follow-up visits at the clinic, where eye images will be taken to assess the rotational stability of the implanted lens.

Read the detailed description

This post-market clinical follow-up (PMCF) study is a prospective, multicenter investigation in European sites. It evaluates the rotational stability of the RayOne Model RAO800S, a non-toric monofocal intraocular lens with orientation marks, following bilateral implantation. Participants will be assessed approximately 5 months (120 to 150 days) post-operatively.

Conditions
IOL, Cataract
Medical subject headings
Intraocular Lymphoma, Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07099079
Study groupRoleWhat they receive
Cataract patientsAdult patients scheduled for routine bilateral cataract surgery as part of their standard clinical care. All participants receive the RayOne RAO800S non-toric monofocal intraocular lens with orientation marks.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Effectiveness Endpoint - IOL rotation

    Percentage of RayOne Model RAO800S IOLs with IOL rotation at Visit 4 (as determined by photographic method using baseline image at day of surgery) less than

    • 10 degrees in 90% of the cases as described in ISO 11979-7:2024.
    • 20 degrees in 95% of the cases as described in ISO 11979-7:2024.

    Measured: 120 to 150 days post-operatively (Visit 4)

Secondary outcomes (3)
  1. Secondary Effectiveness Endpoints - Stability of IOL axis orientation

    Stability of IOL axis orientation, expressed as percentage of IOLs that rotate ≤ 5 degrees postoperatively between 30 to 60 days (Visit 3) and 120 to 150 days (Visit 4) as described in the ANSI Z80.30-2018. This criterium is passed if 90% of the IOLs in the treated eyes rotate ≤ 5 degrees between the mentioned visits.

    Measured: 120 to 150 days post-operatively (Visit 4)

  2. Secondary Effectiveness Endpoints - Axis misalignment

    Axis misalignment, defined as the absolute difference between intended IOL axis orientation and Visit 4, (as determined by photographic method using baseline image at the day of surgery) shall be less than

    • 10 degrees in 90% of the cases as described in ANSI Z80.30-2018
    • 20 degrees in 95% of the cases as described in ANSI Z80.30-2018.

    Measured: 120 to 150 days post-operatively (Visit 4)

  3. Secondary Safety Endpoints - Rate of CDVA 0.30 logMAR

    Rate of CDVA 0.30 logMAR or better at 120 to 150 days post-operatively (Visit 4) shall not exceed the ISO SPE threshold rates as described in ISO 11979-7:2024 (Table E.3)

    Measured: 120 to 150 days post-operatively (Visit 4)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2025
  2. Study startNov 2026 (estimated)
  3. Primary completionNov 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
92 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07099079
Sponsor's protocol ID
HRSS-2025-01
Status last verified
Sep 2026
First submitted
15 Jul 2025
Last updated
10 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of IOL, Cataract, run by Rayner Intraocular Lenses Limited.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Pavel Stodulka, MD, PhD, FEBOS-CR (+420 577 202 2, stodulka@lasik.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Effectiveness Endpoint - IOL rotation (time frame: 120 to 150 days post-operatively (Visit 4)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in